- Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth
- Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)
- Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study
- Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma
Key statistics
As of last trade Polaris Group LLC (6550:TAI) traded at 63.40, 4.79% above its 52-week low of 60.50, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 66.50 |
---|---|
High | 66.50 |
Low | 63.40 |
Bid | 63.40 |
Offer | 63.50 |
Previous close | 66.10 |
Average volume | 1.27m |
---|---|
Shares outstanding | 745.68m |
Free float | 246.28m |
P/E (TTM) | -- |
Market cap | 49.29bn TWD |
EPS (TTM) | -2.28 TWD |
Data delayed at least 20 minutes, as of Jul 29 2024.
More ▼